Ford: Driving Away From The Competition?

Monday, July 27, 2009

Ford: Driving Away From The Competition?

Ford is often recognized "America's Company." From the birth of Ford, all the way to its almost sudden collapse, it has been a storybook company. The new CEO, Alan Mullally, is a young innovative leader, exactly what Ford needs to regain their competitive advantage. Ford has a great opportunity to come out of the recession stronger and more financially sound than before. With the fall of GM, there is a very large void to be filled in market share. Ford currently is in the best position to fill that void. With the "cash for clunkers" program now underway, Ford has a chance to start showing why they are still around. With new models, new leadership, and a much larger market share, Ford is a must own stock. A potential market correction may be looming nearby, so a dip in the broad market would make for a unique buying opportunity.

Risk Level: Moderate

Target Buy Price: $6.75 - $7.15

Current Price: $7.27

1 comment:

MPJuly 28, 2009 at 7:33 PM
With the market's stellar performance last week and today's rally from 100 down to a minimal loss, is this a signal for a long position or are the hedge funds setting us for the short to kill? Do you have any short positions you are considering?
ReplyDelete
Replies

Add comment

In the Stocklight - 2/4/10

Health Discovery Corporation - HDVY

Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze large amounts of data to uncover patterns in the United States. The company’s principal intellectual property includes Support Vector Machines and Fractal Genomic Modeling, as well as biomarkers. Its technologies and discoveries comprise a subset of genes that separates benign prostatic hyperplasia (BPH) from prostate cancer and BPH from normal tissue patterns.

As of recent, HDC has made a buzz with rumors that they may have a new and more effective way of recognizing prostate cancer. They are partnered with Abbot, Quest, and even Pfizer. If they use HDC's biomarker recognition in any commercialization of a product, they will receive 30% of royalties. This is a buy and hold, for the gains could be monumental if the rumors are true.

Disclaimer

The Content does not constitute an offer, solicitation or recommendation to acquire or dispose of any investment or to engage in any other transaction. This Web Site is not directed at or intended for publication or distribution to any person in any jurisdiction where doing so would result in contravention of any applicable laws or regulations. It is the responsibility of the individual user to consider his legal and regulatory position in the relevant jurisdiction, the risks associated with trading such products and to ensure that the use of the Content and the subsequent making of any investment does not contravene any such restrictions or applicable laws and regulations of any jurisdiction. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific security, index, report, opinion, advice or other Content.

BHMP - Money on Wall Street

What company do you think has the best chance to blow up?

Monday, July 27, 2009